Hemant Desai

Array ( [id] => 17398079 [patent_doc_number] => 20220040169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Methods for the Administration of Certain VMAT2 Inhibitors [patent_app_type] => utility [patent_app_number] => 17/506883 [patent_app_country] => US [patent_app_date] => 2021-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17506883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17952367 [patent_doc_number] => 11478439 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Method for alleviating keratoconjunctivitis sicca [patent_app_type] => utility [patent_app_number] => 17/496825 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3005 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17759892 [patent_doc_number] => 20220233504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING LIDOCAINE AND MELATONIN [patent_app_type] => utility [patent_app_number] => 17/488241 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342081 [patent_doc_number] => 20220008412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/449196 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17449196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503304 [patent_doc_number] => 20220096406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION [patent_app_type] => utility [patent_app_number] => 17/477886 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18108107 [patent_doc_number] => 20230000987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/467976 [patent_app_country] => US [patent_app_date] => 2021-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297945 [patent_doc_number] => 20210393784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => INJECTABLE CANNABINOID FORMULATIONS FOR TREATING PAIN [patent_app_type] => utility [patent_app_number] => 17/466087 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690891 [patent_doc_number] => 20230321053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES [patent_app_type] => utility [patent_app_number] => 18/040508 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272853 [patent_doc_number] => 20210379051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS [patent_app_type] => utility [patent_app_number] => 17/400194 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41960 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458658 [patent_doc_number] => 20220071962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => COMPOSITIONS AND METHODS FOR PROVIDING HEALTH BENEFITS IN AN ANIMAL [patent_app_type] => utility [patent_app_number] => 17/398499 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938120 [patent_doc_number] => 20240033259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/019959 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7335 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18509297 [patent_doc_number] => 20230225368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => INSECT LIFE CYCLE INTERRUPTION AGENT(LCIA) FORMULATIONS AND THEIR MANUFACTURE AND USE [patent_app_type] => utility [patent_app_number] => 18/022042 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18022042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938133 [patent_doc_number] => 20240033272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS [patent_app_type] => utility [patent_app_number] => 18/005838 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492617 [patent_doc_number] => 12534479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Triazine compound and composition and use thereof [patent_app_type] => utility [patent_app_number] => 18/015381 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22040 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214402 [patent_doc_number] => 20210347739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => INHIBITION OF OLIG2 ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/367099 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17618400 [patent_doc_number] => 11337423 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-24 [patent_title] => None [patent_app_type] => utility [patent_app_number] => 17/363682 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3808 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18509906 [patent_doc_number] => 20230225992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => LIQUID DISPERSIBLE CURCUMINOID COMPOSITIONS AND METHODS OF IMPROVING COGNITIVE FUNCTION [patent_app_type] => utility [patent_app_number] => 18/012382 [patent_app_country] => US [patent_app_date] => 2021-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140083 [patent_doc_number] => 20210308094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => CESSATION OF ANTI-DEPRESSANT MEDICATION [patent_app_type] => utility [patent_app_number] => 17/351590 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522895 [patent_doc_number] => 20230233544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS [patent_app_type] => utility [patent_app_number] => 18/001519 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597147 [patent_doc_number] => 20230271939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/001317 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001317 [rel_patent_id] =>[rel_patent_doc_number] =>)